S H Thorne

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
    Steve H Thorne
    Bio X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA
    Expert Opin Biol Ther 4:1307-21. 2004
  2. ncbi request reprint Design and testing of novel oncolytic vaccinia strains
    Steve H Thorne
    Division of Surgical Oncology, University of Pittsburgh, PA, USA
    Methods Mol Biol 542:635-47. 2009
  3. pmc Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination
    H Tang
    Department of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Gene Ther 20:770-8. 2013
  4. pmc Theranostic potential of oncolytic vaccinia virus
    Juan J Rojas
    Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    Theranostics 2:363-73. 2012
  5. pmc Importance of glycolysis and oxidative phosphorylation in advanced melanoma
    Jonhan Ho
    Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Mol Cancer 11:76. 2012
  6. doi request reprint The role of GM-CSF in enhancing immunotherapy of cancer
    Steve H Thorne
    University of Pittsburgh Cancer Institute, University of Pittsburgh, 1 46e HCC, 5117 Center Avenue, Pittsburgh, PA 15238, USA
    Immunotherapy 5:817-9. 2013
  7. pmc Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing
    Yoram Barak
    Department of Microbiology and Immunology, Sherman Fairchild Science Building, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305, USA
    BMC Cancer 10:146. 2010
  8. doi request reprint Enhancing biological therapy through conditional regulation of protein stability
    Steve H Thorne
    Departments of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Expert Rev Mol Med 12:e2. 2010
  9. doi request reprint Immunotherapeutic potential of oncolytic vaccinia virus
    Steve H Thorne
    Department of Surgery and Department of Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 1 46e, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Immunol Res 50:286-93. 2011
  10. ncbi request reprint Oncolytic vaccinia virus: from bedside to benchtop and back
    Steve H Thorne
    University of Pittsburgh Cancer Institute and Division of Surgical Oncology, Hillman Cancer Center, 5150 Centre Avenue, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Curr Opin Mol Ther 10:387-92. 2008

Collaborators

  • Y Zhang
  • Christopher H Contag
  • B Huang
  • John Bell
  • Lawrence Lum
  • Y Zou
  • P Sampath
  • H Tang
  • Jonhan Ho
  • Juan J Rojas
  • Yoram Barak
  • David H Kirn
  • John K Chan
  • F Li
  • W Hou
  • X Yan
  • Yan Lin
  • Stergios J Moschos
  • Michelle Barbi de Moura
  • Dorothea Becker
  • Lyn M Duncan
  • Garret Vincent
  • Bennett Van Houten
  • Lin Hui-Min
  • John M Kirkwood
  • Frank Schreiber
  • A Matin
  • Dirk Debeer
  • Yaohe Wang
  • Fabrice Le Boeuf
  • Mobin Karimi
  • Stephan Schulz
  • Chad A Hamilton
  • Jonathan M Gall
  • Robert S Negrin
  • Jeanette Baker
  • Michael K Cheung
  • Nelson N Teng

Detail Information

Publications20

  1. ncbi request reprint Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus
    Steve H Thorne
    Bio X Program, Dept of Pediatrics, School of Medicine, Stanford University, CA, USA
    Expert Opin Biol Ther 4:1307-21. 2004
    ....
  2. ncbi request reprint Design and testing of novel oncolytic vaccinia strains
    Steve H Thorne
    Division of Surgical Oncology, University of Pittsburgh, PA, USA
    Methods Mol Biol 542:635-47. 2009
    ....
  3. pmc Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination
    H Tang
    Department of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Gene Ther 20:770-8. 2013
    ..The unexpected and pleiotropic beneficial anti-tumor effects of doxycycline on both immune cell and oncolytic viral therapies make it an excellent candidate for rapid clinical testing. ..
  4. pmc Theranostic potential of oncolytic vaccinia virus
    Juan J Rojas
    Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    Theranostics 2:363-73. 2012
    ..Possible future applications for reporter gene expression from oncolytic viruses in the phenotyping of tumors and the personalizing of treatment regimens are also discussed...
  5. pmc Importance of glycolysis and oxidative phosphorylation in advanced melanoma
    Jonhan Ho
    Department of Dermatology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Mol Cancer 11:76. 2012
    ....
  6. doi request reprint The role of GM-CSF in enhancing immunotherapy of cancer
    Steve H Thorne
    University of Pittsburgh Cancer Institute, University of Pittsburgh, 1 46e HCC, 5117 Center Avenue, Pittsburgh, PA 15238, USA
    Immunotherapy 5:817-9. 2013
    ....
  7. pmc Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killing
    Yoram Barak
    Department of Microbiology and Immunology, Sherman Fairchild Science Building, Stanford University School of Medicine, 299 Campus Drive, Stanford, CA 94305, USA
    BMC Cancer 10:146. 2010
    ..Whether NO generation by the bacteria has a role in SL7838 lethality to cancer cells is explored. This bacterium has the mechanism for generating NO, but also for decomposing it...
  8. doi request reprint Enhancing biological therapy through conditional regulation of protein stability
    Steve H Thorne
    Departments of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Expert Rev Mol Med 12:e2. 2010
    ....
  9. doi request reprint Immunotherapeutic potential of oncolytic vaccinia virus
    Steve H Thorne
    Department of Surgery and Department of Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 1 46e, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Immunol Res 50:286-93. 2011
    ..Approaches to developing next-generation vectors that are capable of effectively harnessing both of these mechanisms of action are discussed here...
  10. ncbi request reprint Oncolytic vaccinia virus: from bedside to benchtop and back
    Steve H Thorne
    University of Pittsburgh Cancer Institute and Division of Surgical Oncology, Hillman Cancer Center, 5150 Centre Avenue, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Curr Opin Mol Ther 10:387-92. 2008
    ..Preclinical models incorporating new oncolytic vaccinia strains, as well as data from the first clinical trials that have utilized the next-generation oncolytic vaccinia strains for the potential treatment of cancer have been described...
  11. doi request reprint Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery
    S H Thorne
    University of Pittsburgh Cancer Institute, Department of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Gene Ther 15:753-8. 2008
    ..Similarly, if we are to develop targeted therapies that are sufficiently multifaceted to eliminate cancer cells at all stages of disease, we should integrate the virus into the unique biology of the cell delivery vehicle...
  12. doi request reprint Next-generation oncolytic vaccinia vectors
    Steve H Thorne
    Department of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    Methods Mol Biol 797:205-15. 2012
    ....
  13. pmc Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy
    Stephen H Thorne
    University of Pittsburgh Cancer Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15238, USA
    Mol Ther 18:1698-705. 2010
    ..This therefore represents a novel and effective means to overcome localized immune suppression within the tumor microenvironment...
  14. pmc Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells
    Y Zou
    1 Department of Surgey, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA 2 Institute of Clinical and Basic Medical Sciences, The First People s Hospital of Yunnan Province The Kunhua Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
    Br J Cancer 110:1992-9. 2014
    ..Although likely to be mediated by chemokine receptor (CKR) expression, a thorough examination of the mechanism of tumour targeting has not been previously explored...
  15. doi request reprint Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1
    B Huang
    Departments of Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA 15238, USA
    Gene Ther 18:164-72. 2011
    ..These data may provide a direct basis for the design of clinical trials with agents currently in the clinic, as well as providing insight into the development of next generation viral vectors...
  16. pmc Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus
    David H Kirn
    Jennerex Biotherapeutics, San Francisco, California, United States of America
    PLoS Med 4:e353. 2007
    ..We report the construction and preclinical testing of this virus...
  17. pmc Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
    Steve H Thorne
    Department of Pediatrics and Bio X Program, James H Clark Center, Stanford University School of Medicine, Stanford, California, USA
    J Clin Invest 117:3350-8. 2007
    ..JX-963 therefore holds promise as a rationally designed, targeted virotherapeutic for the systemic treatment of cancer in humans and warrants clinical testing...
  18. ncbi request reprint Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors
    Steve H Thorne
    Stanford University, Bio X Programme and Department of Pediatrics, Clark Center, California 94305, USA
    Expert Opin Biol Ther 7:41-51. 2007
    ....
  19. ncbi request reprint Synergistic antitumor effects of immune cell-viral biotherapy
    Steve H Thorne
    Departments of Pediatrics, Radiology, Microbiology, and Immunology Stanford University School of Medicine, Stanford, CA 94305, USA
    Science 311:1780-4. 2006
    ..These results illustrate the potential of combining biotherapeutics for synergistic effects that more effectively treat cancer...
  20. ncbi request reprint Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
    Clin Cancer Res 12:1859-67. 2006
    ..Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor...

Research Grants1